Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prodigiosene ethyl ester 1a is a synthetic C-ring ester-functionalized analog of the natural tripyrrolic pigment prodigiosin. Developed by researchers at Dalhousie University, it acts as a transmembrane anion transporter (specifically facilitating H+/Cl- symport) and uncouples vacuolar-type H+-ATPase (V-ATPase) activity, leading to intracellular acidification and the induction of apoptosis in cancer cells. Additionally, it exhibits copper-mediated double-stranded DNA cleavage. It has demonstrated potent in vitro antiproliferative activity against various cancer cell lines, including breast, colon, lung, leukemia, melanoma, and prostate cancers, and serves as a key synthetic precursor for generating targeted prodigiosene conjugates (such as those linked to estrone, tamoxifen, or folate).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prodigiosene ethyl ester 1a.